Kimmo Porkka

21PUBLICATIONS
248CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingEpidemiological methodsGene expression (incl. microarray and other genome-wide approaches)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Aug 14, 2026
TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

|Mar 11, 2026
Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.

Anton Barchuk, Cesar Barboza, Julieta Politi

|Feb 11, 2026
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Francesco Pignatti, Tarec Christoffer El-Galaly, Martin Kaiser

|Jan 29, 2026
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Diyanath Ranasinghe, Wei-Yu Lin, Sarah E Fordham

|Nov 24, 2025
Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

Samuli Eldfors, Sumit Rai, Vineet Sharma

|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Yingjia Chen, Liye He, Aleksandr Ianevski

Pageof 4

Frequent Collaborators

6 joint publications

Mika Kontro

5 joint publications

Caroline A Heckman

4 joint publications

Bjørn Tore Gjertsen

4 joint publications

Markus Vähä-Koskela